Univariate and multivariate analyses of overall survival
. | . | Univariate analysis . | . | Multivariate analysis . | . | ||
|---|---|---|---|---|---|---|---|
| Variable . | No. . | Hazard ratio (95% CI) . | P . | Hazard ratio (95% CI) . | P . | ||
| Age at transplant | .134 | — | — | ||||
| younger than 40 y | 158 | 1.00 | — | — | |||
| 40 y or older | 75 | 1.32 (0.92-1.90) | — | — | |||
| Clinical subtype | .126 | — | — | ||||
| Indolent | 38 | 1.00 | — | — | |||
| Lymphoblastic | 84 | 1.57 (0.88-2.80) | — | — | |||
| Clinical subtype | .045 | — | — | ||||
| Indolent | 38 | 1.00 | — | — | |||
| Aggressive | 111 | 1.77 (1.01-3.11) | — | — | |||
| Aggressive lymphoma | .004 | — | — | ||||
| PTCL | 22 | 1.00 | — | — | |||
| Non-PTCL | 89 | 3.45 (1.47-7.69) | — | — | |||
| Response to chemotherapy | <.001 | — | — | ||||
| Sensitive | 128 | 1.00 | — | — | |||
| Resistant | 105 | 3.31 (2.30-4.76) | 3.12 (2.16-4.51) | <.001 | |||
| Prior autograft | < .001 | — | — | ||||
| No | 193 | 1.00 | — | — | |||
| Yes | 40 | 2.59 (1.73-3.87) | 2.18 (1.43-3.30) | < .001 | |||
| Prior radiotherapy | < .001 | — | — | ||||
| No | 152 | 1.00 | — | — | |||
| Yes | 81 | 1.99 (1.41-2.83) | 1.47 (1.02-2.11) | .037 | |||
| Years of transplantation | .932 | — | — | ||||
| 1996-2001 | 187 | 1.00 | — | — | |||
| 1990-1995 | 46 | 1.02 (0.67-1.54) | — | — | |||
| Donor | .076 | — | — | ||||
| HLA-matched | 197 | 1.00 | — | — | |||
| HLA-mismatched | 36 | 1.50 (0.96-2.33) | — | — | |||
| HLA-matched donor | .769 | — | — | ||||
| Related | 154 | 1.00 | — | — | |||
| Unrelated | 43 | 0.93 (0.58-1.50) | — | — | |||
| Source of stem cells* | .095 | — | — | ||||
| BM | 159 | 1.00 | — | — | |||
| PBSCs | 70 | 1.37 (0.95-2.00) | — | — | |||
| Conditioning regimen | .107 | — | — | ||||
| TBI-containing | 193 | 1.00 | — | — | |||
| Others | 40 | 1.42 (0.93-2.17) | — | — | |||
| GVHD prophylaxis† | .227 | — | — | ||||
| Cyclosporin + methotrexate | 204 | 1.00 | — | — | |||
| Tacrolimus + methotrexate | 22 | 1.40 (0.81-2.40) | — | — | |||
| Acute GVHD-time‡ | — | 1.25 (0.85-1.84) | .264 | 1.28 (0.87-1.90) | .213 | ||
. | . | Univariate analysis . | . | Multivariate analysis . | . | ||
|---|---|---|---|---|---|---|---|
| Variable . | No. . | Hazard ratio (95% CI) . | P . | Hazard ratio (95% CI) . | P . | ||
| Age at transplant | .134 | — | — | ||||
| younger than 40 y | 158 | 1.00 | — | — | |||
| 40 y or older | 75 | 1.32 (0.92-1.90) | — | — | |||
| Clinical subtype | .126 | — | — | ||||
| Indolent | 38 | 1.00 | — | — | |||
| Lymphoblastic | 84 | 1.57 (0.88-2.80) | — | — | |||
| Clinical subtype | .045 | — | — | ||||
| Indolent | 38 | 1.00 | — | — | |||
| Aggressive | 111 | 1.77 (1.01-3.11) | — | — | |||
| Aggressive lymphoma | .004 | — | — | ||||
| PTCL | 22 | 1.00 | — | — | |||
| Non-PTCL | 89 | 3.45 (1.47-7.69) | — | — | |||
| Response to chemotherapy | <.001 | — | — | ||||
| Sensitive | 128 | 1.00 | — | — | |||
| Resistant | 105 | 3.31 (2.30-4.76) | 3.12 (2.16-4.51) | <.001 | |||
| Prior autograft | < .001 | — | — | ||||
| No | 193 | 1.00 | — | — | |||
| Yes | 40 | 2.59 (1.73-3.87) | 2.18 (1.43-3.30) | < .001 | |||
| Prior radiotherapy | < .001 | — | — | ||||
| No | 152 | 1.00 | — | — | |||
| Yes | 81 | 1.99 (1.41-2.83) | 1.47 (1.02-2.11) | .037 | |||
| Years of transplantation | .932 | — | — | ||||
| 1996-2001 | 187 | 1.00 | — | — | |||
| 1990-1995 | 46 | 1.02 (0.67-1.54) | — | — | |||
| Donor | .076 | — | — | ||||
| HLA-matched | 197 | 1.00 | — | — | |||
| HLA-mismatched | 36 | 1.50 (0.96-2.33) | — | — | |||
| HLA-matched donor | .769 | — | — | ||||
| Related | 154 | 1.00 | — | — | |||
| Unrelated | 43 | 0.93 (0.58-1.50) | — | — | |||
| Source of stem cells* | .095 | — | — | ||||
| BM | 159 | 1.00 | — | — | |||
| PBSCs | 70 | 1.37 (0.95-2.00) | — | — | |||
| Conditioning regimen | .107 | — | — | ||||
| TBI-containing | 193 | 1.00 | — | — | |||
| Others | 40 | 1.42 (0.93-2.17) | — | — | |||
| GVHD prophylaxis† | .227 | — | — | ||||
| Cyclosporin + methotrexate | 204 | 1.00 | — | — | |||
| Tacrolimus + methotrexate | 22 | 1.40 (0.81-2.40) | — | — | |||
| Acute GVHD-time‡ | — | 1.25 (0.85-1.84) | .264 | 1.28 (0.87-1.90) | .213 | ||
CI indicates confidence interval; PTCL, peripheral T-cell lymphoma; HLA, human leukocyte antigen; BM, bone marrow; GVHD, graft-versus-host disease; and —, not applicable.
Those who received cord blood (n = 2) or BM + PBSCs (n = 2) were excluded because of the small number of patients.
Seven patients using other GVHD prophylaxis were excluded.
Acute GVHD was treated as time-dependent variable.